Measuring muscle-tendon properties in a clinical setting in clubfoot patients of different ages
Recruiting
- Conditions
- clubfootcongenital equinovarus talipes10028396
- Registration Number
- NL-OMON56293
- Lead Sponsor
- Maxima Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 35
Inclusion Criteria
- Idiopathic clubfoot patients
- Unilaterally affected
- 2 t/m 11 years old
- Primarily treated with the Ponseti method
- Relapse group: planned for relapse treatment (e.g. but not limited to
tibialis anterior transposition / hemi-epiphysiodesis)
Exclusion Criteria
- Patients with underlying syndromes
- Bilaterally affected patients
- Patients who had primary treatment for their clubfoot other than the Ponseti
method
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>(difference in) calf-muscle volume </p><br>
- Secondary Outcome Measures
Name Time Method <p>secondary muscle-tendon properties such as pennation angle, fiber length and<br /><br>muscle and tendon cross-sectional area<br /><br>functional status of the clubfoot according to the Clubfoot Assessment Protocol<br /><br>clinical status (relapse)<br /><br>age</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do muscle-tendon stiffness and elasticity assessed via 3D ultrasound in NL-OMON56293 correlate with genetic markers in clubfoot patients?
What is the comparative effectiveness of 3D ultrasound-guided therapies versus standard casting in NL-OMON56293 for congenital equinovarus talipes?
Which biomarkers predict response to serial 3D ultrasound assessments in NL-OMON56293 clubfoot management across age groups?
Are there adverse events associated with longitudinal 3D ultrasound monitoring in NL-OMON56293 pediatric clubfoot cases?
How does 3D ultrasound evaluation of muscle-tendon properties in NL-OMON56293 influence targeted pharmacological agent development for clubfoot?